echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Can you tell the clues of Alzheimer's disease from the retina?

    Can you tell the clues of Alzheimer's disease from the retina?

    • Last Update: 2021-09-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Amyloid plaque is a plaque structure formed by abnormal deposits of β-amyloid protein outside brain neurons.
    It hinders some functions and eventually leads to neuronal death.
    This is also considered a sign of Alzheimer's disease (AD)
    .


    But amyloid deposition can also occur on the retina of the eye, and it often occurs in patients who are clinically diagnosed with Alzheimer's


    diagnosis

    In a small cross-sectional study, a research team led by scientists from the University of California San Diego School of Medicine compared amyloid tests in the retina and brain of patients in the two studies, assessing neurodegeneration in people with low amyloid levels.
    How big is the risk
    .


    Researchers have observed that the appearance of retinal spots in the eyes is associated with higher levels of amyloid in brain scans


    The appearance of retinal spots in the eyes is associated with higher levels of amyloid in brain scans


    Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
    DOI: 10.
    1002/dad2.
    12199

    Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
    DOI: 10.
    1002/dad2.
    12199

    Compared with the individuals in the longitudinal evaluation test of amyloid risk and neurodegeneration, the four individuals in this test showed more curcumin-positive spots on the retina.
    There are obvious differences between the two groups.
    Studies on curcumin-labeled amyloid have found that clinical patients have cognitive impairment at an early stage, and retinal inclusions have been observed in preclinical cohort retinal studies
    .


    The researchers demonstrated that an increase in retinal curcumin-positive spots can be detected in asymptomatic individuals with positive amyloid positron emission tomography


    Curcumin binds to amyloid in the body and is used as a contrast agent to identify early cognitive impairment (MCI) and amyloid deposits in the retina of individuals with mild to moderate Alzheimer's
    .


    A recent study using a retinal fundus imaging system reported that in individuals with MCI and AD, the regional increase in retinal spots suggests that regional amyloid deposits may represent the development of the disease


     

    Comparison of retinal amyloid and brain amyloid

    Comparison of retinal amyloid and brain amyloid

    Dr.
    Robert Rissman, professor of neuroscience at the University of California, San Diego School of Medicine, said: "But these findings are encouraging because they show that it is possible to use retinal imaging tests to determine the onset, spread, and morphology of Alzheimer’s disease, rather than through Expensive brain scans
    .


    We look forward to seeing the results of retinal scans at different times, and the impact of Solanezumab monoclonal antibody on retinal imaging


    They show that it is possible to use retinal imaging tests to determine the onset, spread, and morphology of Alzheimer's disease, rather than through expensive brain scans


    Reference materials:

    Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).


    Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
    DOI: 10.
    1002/dad2.
    12199 Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
    DOI: 10.
    1002/dad2 .
    12199 Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.